Limited coverage drugs – granisetron

Last updated on October 24, 2022

Generic name

granisetron

Strength

1 mg, 1 mg/mL

Form

tablet, vial

Special Authority criteria

Approval period

Prevention and treatment of nausea and vomiting associated with chemotherapy First approval: 6 months

Renewals: 6 months

Practitioner exemptions

Practitioners in the following specialties are not required to submit a Special Authority request for coverage:

  • oncologist (medical)
  • oncologist (radiation)

Special notes

  • None

Special Authority requests